APArjun K. Parasher

Arjun K. Parasher

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Arjun K. Parasher has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Correlation between CT imaging and symptom scores in cystic fibrosis associated chronic sinusitis

    by Emily Eischen, Matthew F. Gliksman, Daniel Segarra, Ryan D. Murtagh, Lindsey E. Ryan, Arjun K. Parasher, Mark H. Tabor


  • In‐Hospital Costs for Open versus Endoscopic Endonasal Approach for Craniopharyngioma Resection

    by Arjun K Parasher, David K Lerner, Stephen P. Miranda, Jennifer E. Douglas, Jordan T Glicksman, Tyler Alexander, Theodore Lin, Darren Ebesutani, Michael Kohanski, John Yk Lee, et al.

    Objective: To determine the in‐hospital cost implications of an expanded endoscopic endonasal approach (EEEA) for craniopharyngioma resection relative to the traditional open transcranial approach.Methods: All craniopharyngioma surgeries performed at a single institution over a period from January 1st 2001 to October 31th 2017 were evaluated. The electronic medical record was reviewed for patient factors, tumor characteristics, and cost variables associated with each hospital stay and univariate regression analysis was performed using R software.Results: Thirty‐six patients met study criteria, including 22 undergoing an open approach and 14 undergoing an EEEA. There was a significantly longer average length of stay among patients undergoing open resection (21.5 vs. 10.6 days, p = 0.024). The average total in‐hospital cost of a patient undergoing an EEEA was $58979.3 compared to $89142.3 for an open approach (p = 0.127). On univariate regression analysis, the total in‐hospital cost for a patient undergoing an open approach relative to an EEEA was $30163.0 (p = 0.127). The open approach was exclusively performed from study onset until April 2010 (16 patients). From April 2010 to August 2013, 6 open approaches and 5 EEEA were performed. The EEEA has been exclusively performed from August 2013 until the conclusion of our study period (9 patients).Conclusions: There has been a shift toward surgical resection of craniopharyngioma via an EEEA approach for amenable tumors. Our study demonstrates that the EEEA has become the preferred surgical approach at our institution, and shows that the EEEA is associated with shorter postoperative length of stay and lower total in‐hospital cost. Laryngoscope, 133:83–87, 2023


  • Economic Evaluation of Dupilumab Versus Endoscopic Sinus Surgery for the Treatment of Chronic Rhinosinusitis With Nasal Polyps

    by Arjun K. Parasher, Matt Gliksman, Daniel Segarra, Theodore Lin, Luke Rudmik, Troy Quast

    Background: Dupilumab is a novel monoclonal antibody that recently received US Food and Drug Administration approval for the treatment of chronic rhinosinusitis with nasal polyps. Endoscopic sinus surgery (ESS) has been the mainstay of treatment for patients refractory to initial medical therapy. Data comparing the cost‐effectiveness of these treatments are scarce. The objective of this study is to compare the cost‐effectiveness of dupilumab and ESS treatment for patients with chronic rhinosinusitis with nasal polyps refractory to medical therapy.Methods: A cohort‐style Markov decision tree economic evaluation with 10‐year time horizon was performed. The two comparative treatment strategies were dupilumab therapy or ESS followed by postoperative maintenance therapy. Patients with response to treatment continued with either maintenance or dupilumab therapy; patients with no response underwent ESS. The primary outcome measure was incremental cost per quality‐adjusted life‐year calculated from Sino‐Nasal Outcome Test (SNOT‐22) scores. Sensitivity analyses were performed including discounting scenarios and a probabilistic sensitivity analysis.Results: The dupilumab strategy cost $195,164 and produced 1.779 quality‐adjusted life‐years. The ESS strategy cost $20,549 and produced 1.526 quality‐adjusted life‐years. This implies an incremental cost of $691,691 for dupilumab for every 1‐unit increase in quality‐adjusted life‐year compared with ESS. Probability sensitivity analysis indicated that ESS was more cost‐effective than dupilumab in all iterations.Conclusions: While dupilumab and ESS may demonstrate similar clinical effectiveness, ESS remains the most cost‐effective treatment option and should remain the standard of care for patients with chronic rhinosinusitis with nasal polyps refractory to medical therapy.


  • Open Access

    Systematic review of outcomes for endoscopic sinus surgery and subsequent aspirin desensitization in aspirin‐exacerbated respiratory disease

    by Lindsey Ryan, Daniel Segarra, Mark Tabor, Arjun Parasher

    Objective: To review and evaluate outcomes of patients with aspirin‐exacerbated respiratory disease (AERD) following endoscopic sinus surgery and subsequent aspirin desensitization.Methods: Electronic searches of OVID MEDLINE (1948 to September 10, 2019), EMBASE (1980 to September 10, 2019), and PubMed were performed on September 10, 2019. A systematic review of the literature was performed using the 2009 PRISMA guidelines. Studies with both preoperative and postoperative data for patients with AERD who underwent sinus surgery and aspirin desensitization were considered appropriate for inclusion. Publications were written in English and included patients aged 18 years or older.Results: Six studies met inclusion criteria for this systematic review. The primary outcome measure was change in symptom profile measured by patient‐reported quality of life scores. The results demonstrate statistically significant improvement in symptoms following endoscopic sinus surgery, with sustained improvement following aspirin desensitization. Revision surgery rates were significantly lower in patients maintained on aspirin therapy.Conclusion: This review suggests that surgery followed by aspirin desensitization results in improvement in both subjective and objective outcome measures. The adjunctive use of aspirin desensitization allows for long‐term stability in symptom scores. Recurrence of polyps and worsening symptoms requiring revision surgery occurs when aspirin maintenance therapy is interrupted.


  • Drivers of In‐Hospital Costs Following Endoscopic Transphenoidal Pituitary Surgery

    by Arjun K. Parasher, David K. Lerner, Jordan T. Glicksman, Stephen P. Miranda, Ryan Dimentberg, Darren Ebesutani, Michael Kohanski, John Y. K. Lee, Phillip B. Storm, Bert W. O'MAlley, et al.

    Objective: To characterize the patient and clinical factors that determine variability in hospital costs following endoscopic transphenoidal pituitary surgery.Methods: All endoscopic transphenoidal pituitary surgeries performed from January 1, 2015, to October 24, 2017, with complete data were evaluated in this retrospective single‐institution study. The electronic medical record was reviewed for patient factors, tumor characteristics, and cost variables during each hospital stay. Multivariate linear regression was performed using Stata software.Results: The analysis included 190 patients and average length of stay was 4.71 days. Average total in‐hospital cost was $28,624 (95% confidence interval $25,094–$32,155) with average total direct cost of $19,444 ($17,136–$21,752) and total indirect cost of $9181 ($7592–$10,409). On multivariate regression, post‐operative cerebrospinal fluid (CSF) leak was associated with a significant increase in all cost variables, including a total cost increase of $40,981 ($15,474–$66,489, P = .002). Current smoking status was associated with an increased total cost of $20,189 ($6,638–$33,740, P = .004). Self‐reported Caucasian ethnicity was associated with a significant decrease in total cost of $6646 (−$12,760 to −$532, P = .033). Post‐operative DI was associated with increased costs across all variables that were not statistically significant.Conclusions: Post‐operative CSF leak, current smoking status, and non‐Caucasian ethnicity were associated with significantly increased costs. Understanding of cost drivers of endoscopic transphenoidal pituitary surgery is critical for future cost control and value creation initiatives.Level of Evidence: 3 Laryngoscope, 131:760–764, 2021